Medicine Information

Ligazid MX

Name: Ligazid MX
Brand: Ligazid MX
Rating: 4.5 (117 reviews)

Tablet5 mgOral Hypoglycemic Agent, AntidiabeticATC: A10BB09

Generic Name

Gliclazide (Modified Release) 5 mg Tablet

Manufacturer

Square Pharmaceuticals Ltd.

Country

Bangladesh

Loading images...

Price Details

Current market pricing information

Variant	Unit Price	Strip Price
ligazid mx 5 mg tablet	৳ 20.00	৳ 120.00

Description

Overview of the medicine

Ligazid MX 5 mg Tablet contains Gliclazide (Modified Release), an oral antidiabetic drug belonging to the sulfonylurea class. It is used to control blood sugar levels in patients with Type 2 Diabetes Mellitus when diet and exercise alone are not sufficient. The modified release formulation ensures a sustained therapeutic effect throughout the day.

Uses & Indications

Management of Type 2 Diabetes Mellitus in adults.

Adjunct to diet and exercise to improve glycemic control.

Monotherapy or in combination with other antidiabetic agents (e.g., metformin).

Dosage

Adults

The usual starting dose of Gliclazide MR is typically 30 mg once daily. For a hypothetical 5 mg MR formulation, the initial dose may be 5 mg once daily, adjusted based on blood glucose levels and clinical response. Maximum dose for Gliclazide MR is generally 120 mg once daily.

Elderly

Similar to adults, but with careful monitoring of blood glucose to avoid hypoglycemia. Initial dose may be lower.

Renal_impairment

Mild to moderate renal impairment usually does not require dose adjustment. Severe renal impairment (CrCl < 30 mL/min) is generally contraindicated due to increased risk of hypoglycemia. Consult physician.

How to Take

Ligazid MX 5 mg Tablet should be taken orally once daily with breakfast. Swallow the tablet whole with water, do not crush or chew. Taking it with a meal helps reduce gastrointestinal side effects and the risk of hypoglycemia.

Mechanism of Action

Gliclazide stimulates insulin secretion from the pancreatic beta cells by binding to sulfonylurea receptors on the cell surface. This binding leads to the closure of ATP-sensitive potassium channels, causing depolarization and subsequent calcium influx, which triggers insulin release. It also has hemovascular effects, reducing platelet aggregation and improving fibrinolysis.

Pharmacokinetics

Onset

Onset of action typically within a few hours.

Excretion

Primarily excreted in urine (less than 1% unchanged) and feces.

Half life

Approximately 12-20 hours for the modified release formulation.

Absorption

Well absorbed after oral administration. The modified release formulation ensures gradual and sustained absorption.

Metabolism

Extensively metabolized in the liver by CYP2C9.

Side Effects

Contraindications

Hypersensitivity to gliclazide or other sulfonylureas
Type 1 Diabetes Mellitus
Diabetic ketoacidosis
Severe renal or hepatic impairment
Concomitant treatment with miconazole

Drug Interactions

Alcohol

Increases the hypoglycemic effect, can lead to severe hypoglycemia.

Miconazole

Increases the hypoglycemic effect of gliclazide, potentially leading to severe hypoglycemia. Concomitant use is contraindicated.

Beta-blockers

May mask symptoms of hypoglycemia and potentiate hypoglycemic effect.

Phenylbutazone (systemic route)

Increases the hypoglycemic effect of gliclazide (displaces protein binding), consider another anti-inflammatory agent.

Corticosteroids, Diuretics, Danazol

May decrease the hypoglycemic effect of gliclazide.

Storage

Store below 30°C in a dry place, away from light and moisture. Keep out of reach of children.

Overdose

Overdose of Gliclazide can lead to severe hypoglycemia. Symptoms include sweating, shakiness, confusion, rapid heartbeat, hunger, and in severe cases, seizures, coma. Management involves immediate administration of glucose (oral glucose for conscious patients, IV glucose for unconscious patients) and careful monitoring of blood glucose levels for at least 24-48 hours. Hospitalization may be required.

Pregnancy & Lactation

Gliclazide is generally not recommended during pregnancy. Insulin is preferred for glycemic control during pregnancy. It is unknown whether gliclazide is excreted in human milk, so it is generally not recommended during breastfeeding.

Frequently Asked Questions

Common questions about this medicine

Pack Sizes

10 tablets per blister, 3 blisters per box (30 tablets)10 tablets per blister, 10 blisters per box (100 tablets)

Shelf Life

24-36 months from the date of manufacture, specific to the product.

Availability

Pharmacies, hospitals, clinics

Approval Status

Approved by DGDA (Bangladesh)

Patent Status

Off-patent

WHO Essential Medicine

Yes

Clinical Trials

Extensive clinical trials have established the efficacy and safety of Gliclazide in the management of Type 2 Diabetes Mellitus. Ongoing research may explore its long-term cardiovascular benefits.

Lab Monitoring

Regular monitoring of blood glucose levels (fasting and post-prandial)
HbA1c levels every 3-6 months
Renal function (creatinine, eGFR) periodically
Liver function tests (ALT, AST) periodically

Doctor Notes

Counsel patients on hypoglycemia symptoms and management.
Emphasize lifestyle modifications (diet, exercise).
Monitor renal and hepatic function, especially in elderly patients.
Avoid co-administration with miconazole due to high risk of severe hypoglycemia.

Patient Guidelines

Take your medicine regularly as prescribed by your doctor.
Do not skip meals and try to maintain a consistent meal schedule.
Monitor your blood glucose levels regularly as instructed.
Be aware of symptoms of hypoglycemia and how to treat them (e.g., carry glucose tablets or candy).
Inform your doctor about all other medications, supplements, and herbal products you are taking.

Missed Dose Advice

If you miss a dose, take it as soon as you remember, unless it is almost time for your next dose. In that case, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to make up for a missed one.

Driving Precautions

Gliclazide can cause hypoglycemia, which may impair your ability to drive or operate machinery. Patients should be aware of the symptoms of hypoglycemia and take precautions before driving, especially when initiating treatment or adjusting dosage.